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Abstract 
The co-existence of breast and ovarian cancers in the same individual should raise suspicion of a hereditary process. Patients with either 
BRCA1 or BRCA2 germ-line mutations have an average risk of 39% and 11% respectively of developing ovarian cancer by the age of 
70; they have a risk of 35–85% of developing breast cancer in their lifetime . We report here unusual pathologic features in a BRCA2 
germ-line mutation carrier recently diagnosed with synchronous breast and ovarian cancers, and summarize the findings in six other 
women who were diagnosed with ovarian cancer either simultaneously with the diagnosis of breast cancer or at varying times after the 
diagnosis. While in most instances this may be a coincidental occurrence in highly susceptible individuals, the patient we highlight raises 
the provocative hypothesis that at times breast cancer metastasizes to the ovaries of mutation carriers and stimulates the development of 
an ovarian cancer as well as other cancers. In addition, these ovarian cancers may have different mechanisms of metastases 
predisposing them to travel to unusual sites.
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Introduction 
The co-existence of breast and ovarian cancers in the same 
individual should raise suspicion of a hereditary process. 
Patients with either BRCA1 or BRCA2 germ-line mutations have 
an average risk of 39% and 11% respectively of developing 
ovarian cancer by the age of 70; they have a risk of 35–85% of 
developing breast cancer in their lifetime. The presence of these 
mutations is approximately one in 400 and one in 600, 
respectively, in the general population; but in certain ethnic 
groups, such as the Ashkenazi Jewish population, these 
mutations are found at an increased incidence of more than 2%. 
We report here unusual pathologic features in a BRCA2 germ-
line mutation carrier recently diagnosed with synchronous 
breast and ovarian cancers and summarize the findings in six 
other women who were diagnosed with ovarian cancer either 
simultaneously with the diagnosis of breast cancer or at varying 
times after the diagnosis. While in most instances this may be a 
coincidental occurrence in highly susceptible individuals, the 
patient we highlight raises the provocative hypothesis that at 
times breast cancer metastasizes to the ovaries of mutation 
carriers and stimulates the development of an ovarian cancer as 
well as other cancers. In addition, these ovarian cancers may 
have different mechanisms of metastases predisposing them to 
travel to unusual sites. 
 
Patients 
Table 1 provides demographic details of the patients' 
diagnoses, together with clinical features and BRCA germ-line 
mutation status. We provide the clinical and pathological 
features of patient 1, who was identified to have the BRCA2 
mutation (after her brother as well as paternal cousins were 
diagnosed with breast cancer) in greater detail because of the 
unusual pathology observed in this synchronous presentation: 
the histology in the ovary is somewhat consistent with 
metastases from the breast, but peritoneal metastases that 
were identified had a distinct papillary serous morphology 
indicating a different primary. 
Patient 1: clinical and pathological findings 
This 73-year-old woman, previously in good health, felt a mass 
in her left breast. Following mammographic evaluation, she had 
fine-needle aspiration revealing invasive ductal carcinoma. She 
underwent lumpectomy and sentinel node biopsy; the tumour
was a 2.5-cm infiltrating ductal carcinoma with medullary 
features (Figure 1). Two of ten axillary nodes were involved with 
cancer. The oestrogen receptors (ER) and progesterone 
receptors (PR) were strongly positive, and the Her2 was not 
over-expressed. A staging PET/CT was obtained because of 
vague, but persistent, abdominal symptoms and 19F-
deoxyglucose uptake was present in a left-adnexal mass (4.1 × 
2.5 cm) and a 3.9-cm mass in the peritoneal cavity. This led to a 
laparoscopic resection during which frozen sections of the left 
tube and ovary were consistent with metastatic carcinoma from 
primary mammary cancer. Resection of pelvic organs and the 
omental peritoneal mass by the splenic flexure was deemed 
appropriate. Subsequent sections confirmed the left ovary to be 
replaced by a metastatic cancer with medullary features (Figure 
2), while the omental mass had classical features of papillary 
serous cancer (Figure 3). The sigmoid fat tissue had 
involvement of metastatic adenocarcinoma of mammary origin. 
The patient was treated with carboplatin + paclitaxel with 
normalization of the PET/CT. Since both cancers appeared to 
co-exist, it was decided to proceed with additional 
chemotherapy with carboplatin + liposomal doxorubicin, 
followed by maintenance liposomal doxorubicin, which she 
remained on for ten months without evidence of relapse. In 
addition, she began treatment with anastrozole, which is 
planned for five years (in the absence of relapse). The 
significance of her family history became apparent after genetic 
testing revealed a BRCA2 mutation. 
Of note, one year later, patient complained of mild left upper 
quadrant abdominal pain. A PET/CT was performed that 
showed a 2.5-cm mass with elevated SUV around the 
pancreas. The patient was referred to a surgeon who performed 
a diagnostic laparoscopy. At that time, a small liver mass was 
found and was biopsied. The mass showed metastatic 
adenocarcinoma of pancreaticobiliary origin. The tumour had a 
complex glandular architecture composed of cuboidal to tall 
columnar cells with basophilic vacuolated cytoplasm and 
irregular hyperchromatic nuclei and prominent nucleoli. 
Numerous mitotic figures were seen. Immunohistochemical 
stains showed strong and diffuse positivity for CK7 and CD20 
and negativity for CDX2, oestrogen receptor and WT-1. 
 
Pathology 
Histologic examination of the lumpectomy specimen (Figure 1) 
shows a 1.4-cm invasive ductal adenocarcinoma with medullary  
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Table 1: Characteristics of sample patients with both breast and ovarian cancer diagnoses 
 
 
Figure 1: Histologic examination of the breast mass showed a high-grade carcinoma with pleomorphic nuclei and prominent nucleoli 
infiltrating predominantly in sheets with occasional glandular formations. A prominent lymphoplasmacytic infiltrate surrounds clusters of 
tumour cells. (Haematoxylin and eosin, ×200).
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Figure 2: Histologic examination of the left-ovarian mass shows a histologic picture similar to the breast carcinoma with sheets of high-grade 
tumour cells surrounded by a lymphoplasmacytic infiltrate. Mitotic figures are easily identified. (Haematoxylin and eosin, ×200). 
 
Figure 3: Histologic examination of the omental mass shows tumour cells arranged in papillary groupings with numerous psammoma bodies. 
A lymphoplasmacytic infiltrate is not seen. (Hematoxylin and eosin, ×200). 
features. The tumour cells were arranged in sheets with rare 
tubular formations surrounded by a prominent 
lymphoplasmacytic infiltrate. The tumour cells were pleomorphic 
with marked variation in size and shape, coarse chromatin and 
prominent nucleoli. Mitotic figures were numerous. No in situ 
carcinoma was identified. Immunohistochemical stains were 
positive for oestrogen and progesterone receptors and negative 
for her-2-neu. 
A total abdominal hysterectomy and bilateral salpingo-
oophorectomy with omental biopsy and pelvic lymph node 
dissection was also performed. Grossly, the left ovary contained 
a well-defined tan, homogeneous nodule that extended from the 
ovarian surface into the parenchyma. It measured 1.7 cm in 
greatest dimension. The distal portion of the left fallopian tube 
was adherent to this ovarian nodule. Within the omental tissue, 
a 6-cm well-defined tan, haemorrhagic nodule was noted. The 
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uterus showed several intramural leiomyomas. The pelvic lymph 
nodes were of normal size and shape. 
Microscopically, the left ovary showed a high-grade 
adenocarcinoma composed of sheets of tumour cells with a 
predominantly solid pattern and focal glandular differentiation 
(Figure 2). The sheets of tumour cells were surrounded by a 
lymphoplasmacytic infiltrate. The tumour cells were pleomorphic 
with prominent nucleoli. Mitotic figures were easily identified. 
The omental mass showed a different histologic picture with a 
papillary growth pattern (Figure 3), a lack of a 
lymphoplasmacytic infiltrate and numerous psammoma bodies 
diagnostic of a papillary serous adenocarcinoma. While the 
breast and ovarian masses appeared histologically similar and 
quite different from the omental mass, the immunohistochemical 
pattern of the ovarian mass and omental mass were similar, 
showing positivity for oestrogen receptor, p53, CA125 and 
negativity for progesterone receptor. The breast tissue was not 
stained for CA125 but was negative for p53 and positive for 
progesterone receptor. 
In addition to patient 1, patient 2 had a synchronous 
presentation that caused some diagnostic problems: she was 
initially treated with tamoxifen in view of an oestrogen-receptor-
positive breast cancer but had progression of disease with 
peritoneal carcinomatosis from her ovarian cancer. This showed 
some response to carboplatin + paclitaxel and subsequently to 
the pegylated lipsomal doxorubicin prior to the development of 
recurrent ascites that led to her eventual death. In patient 3, the 
course was that of a fairly typical platinum-sensitive ovarian 
cancer that eventually recurred in the liver and had only 
transient responses. Patient 4 did not demonstrate diagnostic 
dilemmas, was treated for her subsequent development of 
ovarian cancer and has not developed metastases at this point. 
Patients 5, 6 and 8 manifested ovarian cancers at various times 
after the diagnosis of breast cancer. Peritoneal carcinomatosis 
predominated in all three, but two developed unusual sites of 
metastases from ovarian cancer such as brain, bone and lymph 
nodes as well as abnormalities in CA27.29 that behaved 
somewhat discordantly with CA125. Patient 6 was not tested, 
but her family history included breast cancer in several 
members of her family and a fatal pancreatic cancer in her son, 
making the mutation likely. The pathologic diagnosis of ovarian 
cancer in patient 8 was histologically quite similar to her triple 
negative breast cancer; she responded initially to platinum-
based chemotherapy and progressive disease in the 
peritoneum predominated and eventually led to her death. 
Although she herself had not been tested for germ-line 
mutations, her two daughters have tested positive for 
muBRCA1.  
 
Discussion 
The histological findings in the patient reported in full (and also 
other findings in several other patients listed) have raised the 
intriguing possibility that the ovarian cancer diagnosis 
represents metastases from the breast cancer. Some of the 
clinical features suggest that both diagnoses may at times co-
exist. Perhaps these breast cancer cells lay dormant until a new 
ovarian cancer development changes the milieu of the 
surrounding areas and sparks proliferation. 
The presence of BRCA mutations may make ovarian cancers 
more amenable to treatment with DNA damaging drugs such as 
platinums. Whether this also pertains to breast and pancreatic 
cancers arising in a BRCA mutated background has not been 
well studied but has been proposed. Awareness of issues in the 
diagnosis of these patients’ diseases may enable clinicians to 
formulate appropriate therapeutic plans, taking into account the 
possibility of some diagnostic ambiguities as well as the 
importance of establishing the presence of BRCA mutations. As 
more cases are studied, differences may emerge between 
tumours arising in a BRCA1 versus BRCA2 mutation 
background. 
In presenting the range of findings in these patients, we 
conclude that a coincidental co-existence of breast and ovarian 
cancers is likely to account for clinical findings. Breast cancer 
being most common and more likely to appear at an early age, 
usually precedes the ovarian cancer, but in two instances (both 
BRCA2 mutation carriers) these cancers occurred 
synchronously, leading to diagnostic challenges. Even in 
metachronous presentations, however, overlapping histological 
findings, unusual site of metastases for ovarian cancer, such as 
brain and bone, and co-expression of epithelial markers CA125 
and CA27.29 may add to the diagnostic dilemma. The most 
important implication for treatment, however, may lie in 
establishing the presence of the mutation and the enhanced 
susceptibility of these tumours to DNA damaging agents. 
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